重组人生长激素治疗特发性矮小症的效果分析  

Analysis on Effect of Recombinant Human Growth Hormone in Treatment of Idiopathic Short Stature

作　　者：余珊 聂小红[1] Yu Shan;Nie Xiaohong(People's Hospital of Macheng City,Macheng 438300,Hubei Province,China)

机构地区：[1]麻城市人民医院,湖北麻城438300

出　　处：《中国社区医师》2024年第18期56-58,共3页Chinese Community Doctors

摘　　要：目的:探讨重组人生长激素在特发性矮小症患儿中的应用效果。方法:选取2020年5月—2022年3月麻城市人民医院收治的特发性矮小症患儿68例作为研究对象,根据随机数字表法分为对照组与观察组,各34例。对照组给予常规营养治疗,观察组在对照组基础上给予重组人生长激素治疗。比较两组生长速度、体质量、血清胰岛素样生长因子-1(IGF-1)水平、胰岛素样生长因子结合蛋白-3(IGFBP-3)水平、维生素D水平及并发症发生情况。结果:治疗前,两组生长速度、体质量比较,差异无统计学意义(P>0.05);治疗后,两组生长速度、体质量高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.001)。治疗前,两组IGF-1、IGFBP-3、维生素D水平比较,差异无统计学意义(P>0.05);治疗后,两组IGF-1、IGFBP-3、维生素D水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.001)。两组并发症总发生率比较,差异无统计学意义(P>0.05)。结论:重组人生长激素治疗特发性矮小症的效果较好,能够促进患儿生长发育,提高生长相关因子水平,且安全性较高。Objective:To investigate the application effect of recombinant human growth hormone in children with idiopathic short stature.Methods:A total of 52 children with idiopathic short stature admitted to People's Hospital of Macheng City from May 2020 to March 2022 were selected as the study subjects.They were divided into the control group and the observation group by random number table method,with 34 cases in each group.The control group received conventional nutritional therapy,and the observation group received recombinant human growth hormone therapy on the basis of the control group.Growth rate,body weight,serum insulin-like growth factor-1(IGF-1)level,insulin-like growth factor-binding protein-3(IGFBP-3)level,vitamin D level and complications were compared between the two groups.Results:Before treatment,there was no significant difference in growth rate and body weight between the two groups(P>0.05).After treatment,the growth rate and body weight in the two groups were higher than those before treatment,these indexes in the observation group were higher than those in the control group,and the difference was statistically significant(P<0.001).Before treatment,there was no significant difference in the levels of IGF-1,IGFBP-3 and vitamin D between the two groups(P>0.05).After treatment,the levels of IGF-1,IGFBP-3 and vitamin D in the two groups were higher than those before treatment,the levels in the observation group were higher than those in the control group,and the difference was statistically significant(P<0.001).There was no significant difference in the total incidence of complications between the two groups(P>0.05).Conclusion:Recombinant human growth hormone has a good effect in the treatment of idiopathic short stature,and can promote the growth and development of children,increase the level of growth-related factors,and have a high safety.

关 键 词：特发性矮小症 重组人生长激素 体质量 生长速度 

分 类 号：R725.8[医药卫生—儿科]